American Lithium
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Well the patent provides protect for a longer

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BioChica Member Profile
 
Followed By 34
Posts 8,643
Boards Moderated 0
Alias Born 01/06/11
160x600 placeholder
Gibbs Law Group Files Class Action Lawsuit Alleging Violations of Federal Securities Laws Business Wire - 2/22/2019 6:18:00 PM
Amarin To Report Fourth Quarter and Full Year 2018 Results and Host Conference Call on February 27, 2019 GlobeNewswire Inc. - 2/19/2019 6:00:00 AM
Amarin to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire Inc. - 2/14/2019 6:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2019 4:35:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/8/2019 4:33:41 PM
New REDUCE-IT™ Trial Data Showing the Total Reduction in Ischemic Events Accepted for Presentation at the American Colleg... GlobeNewswire Inc. - 1/23/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/4/2019 4:43:20 PM
Amarin Provides Preliminary 2018 Results and 2019 Outlook GlobeNewswire Inc. - 1/4/2019 4:15:00 PM
Amarin to Present at 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 GlobeNewswire Inc. - 1/2/2019 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:35:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:34:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/29/2018 4:08:05 PM
Securities Registration (ads, Immediate) (f-6ef) Edgar (US Regulatory) - 11/29/2018 3:07:20 PM
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference GlobeNewswire Inc. - 11/28/2018 6:25:36 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/28/2018 5:24:09 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 8:59:19 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/26/2018 5:32:33 PM
Amarin Announces Proposed Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 4:23:58 PM
Amarin to Present at the Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/20/2018 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/14/2018 6:03:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 6:18:24 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... PR Newswire (US) - 11/11/2018 10:32:00 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... GlobeNewswire Inc. - 11/10/2018 3:00:00 PM
Amarin to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire Inc. - 11/8/2018 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/7/2018 4:13:25 PM
BioChica   Tuesday, 02/12/19 11:22:38 AM
Re: HerbieRay post# 175795
Post # of 177274 
Well the patent provides protect for a longer period than FDA can provide like NCE protection etc. The patents are very important because the FDA will have them listed in the Orange Book. The question is when Amarin submits the sNDA? Will Vascepa be approved for weight loss if included in submission.

This could be very big in the long run! I hope we see the information released from Reduce-It results soon. Weight Loss has not been publicized yet from what I have seen.




Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist